Effects of prolonged selective serotonin reuptake inhibition on the development and expression of l-DOPA-induced dyskinesia in hemi-parkinsonian rats

Neuropharmacology

Volumn 77, Issue , 2014, Pages 1-8

  Conti, Melissa M ^a   Ostock, Corinne Y ^a   Lindenbach, David ^a   Goldenberg, Adam A ^a   Kampton, Elias ^a   Dell'Isola, Rich ^a   Katzman, Aaron C ^a   Bishop, Christopher ^a  

^a BINGHAMTON UNIVERSITY   (United States)

Author keywords

Abnormal involuntary movements; Dopamine; Parkinson's disease; Selective serotonin reuptake inhibitor; Serotonin transporter

Indexed keywords

CITALOPRAM; LEVODOPA; PAROXETINE; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; CORPUS STRIATUM; DRUG EFFECT; DRUG MECHANISM; DYSKINESIA; LONG TERM CARE; MALE; MOTOR PERFORMANCE; NERVE CELL PLASTICITY; NEUROCHEMISTRY; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; RAT; SEROTONINERGIC NERVE CELL;

3,4-DIHYDROXYPHENYLACETIC ACID; 5-HIAA; 5-HT; 5-HT(1A) RECEPTOR; 5-HYDROXYINDOLEACETIC ACID; 6-HYDROXYDOPAMINE; 6-OHDA; ABNORMAL INVOLUNTARY MOVEMENTS; AIMS; ALO; AXIAL, LIMB AND OROLINGUAL; BENSERAZIDE; DA; DAT; DIMETHYL SULFOXIDE; DL-SERINE 2-(2,3,4-TRIHYDROXYBENZYL) HYDRAZINE HYDROCHLORIDE; DMSO; DOPAC; DOPAMINE; DOPAMINE TRANSPORTER; FAS; FOREPAW ADJUSTING STEPS TEST; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HPLC; L-DOPA-INDUCED DYSKINESIA; LID; MEDIAL FOREBRAIN BUNDLE; MFB; N-[2-[4-(2-METHOXYPHENYL)-1-PIPERAZINYL]ETHYL]-N-2-PYRIDINYLCYCLOHEXANECARBOXAMIDE MALEATE SALT; NE; NOREPINEPHRINE; PARKINSON'S DISEASE; PD; SELECTIVE 5-HT REUPTAKE INHIBITOR; SELECTIVE SEROTONIN REUPTAKE INHIBITOR; SEROTONIN; SEROTONIN TRANSPORTER; SERT; SSRI; WAY100635;

ANIMALS; CITALOPRAM; CORPUS STRIATUM; DOPAMINE; DYSKINESIA, DRUG-INDUCED; LEVODOPA; MALE; MOTOR ACTIVITY; OXIDOPAMINE; PARKINSON DISEASE, SECONDARY; PAROXETINE; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN UPTAKE INHIBITORS;

EID: 84885415685     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2013.09.017     Document Type: Article

References (53)

1. R. Arai, N. Karasawa, M. Geffard, and I. Nagatsu l-DOPA is converted to dopamine in serotonergic fibers of the striatum of the rat: a double-labeling immunofluoresence study Neurosci. Lett. 195 1995 195 198
2. W. Bara-Jiminez, F. Bibbiani, M. Morris, T. Dimitrova, A. Sherzai, M. Mouradian, and T. Chase Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease Mov. Disord. 20 2005 932 936 (Pubitemid 41419506)
3. S. Benmansour, W. Owens, M. Cecchi, D. Morilak, and A. Frazer Serotonin clearance in vivo is altered to a greater extent by antidepressant-induced downregulation of the serotonin transporter than by acute blockade of this transporter J. Neurosci. 22 2002 6766 6772 (Pubitemid 35386433)
4. F. Bibbiani, J. Oh, and T. Chase Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models Neurology 57 2001 1829 1834 (Pubitemid 33096691)
5. C. Bishop, J. George, W. Buchta, A. Goldenberg, M. Mohamed, S. Dickinson, S. Eissa, and K. Eskow Jaunarajs Serotonin transporter inhibition attenuates l-DOPA-induced dyskinesia without compromising l-DOPA efficacy in hemi-parkinsonian rats Eur. J. Neurosci. 36 2012 2839 2848
6. P. Blier, R. Bergeron, and C. de Montigny Selective activation of postsynaptic 5-HT1A receptors induces rapid antidepressant response Neuropsychopharmacology 16 1997 333 338 (Pubitemid 27211731)
7. V. Bonifati, E. Fabrizio, R. Cipriani, N. Vanacore, and G. Meco Buspirone in levodopa- induced dyskinesias Clin. Neuropharmacol. 17 1994 73 82
8. I. Branchi, I. D'Andrea, M. Armida, T. Cassano, A. Pèzzola, R. Potenza, M. Morgese, P. Popoli, and E. Alleva Nonmotor symptoms in Parkinson's disease: investigating early-phase onset of behavioral dysfunction in the 6-hydroxydopamine-lesioned rat model J. Neurosci. Res. 86 2008 2050 2061
9. M. Brocco, A. Dekeyne, S. Veiga, S. Girardon, and M. Millan Induction of hyperlocomotion in mice exposed to a novel environment by inhibition of serotonin reuptake; a pharmacological characterization of diverse classes of antidepressant agents Pharmacol. Biochem. Behav. 71 2002 667 680 (Pubitemid 34219217)
10. F. Bymaster, W. Zhang, P. Carter, J. Shaw, E. Chernet, L. Phebus, D. Wong, and K. Perry Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex Psychopharmacology 160 2002 353 361 (Pubitemid 34253277)
11. M. Carta, T. Carlsson, D. Kirik, and A. Björklund Dopamine released from 5-HT terminals is the cause of l-DOPA-induced dyskinesia in parkinsonian rats Brain 130 2007 1819 1833 (Pubitemid 47343795)
12. J. Casanovas, M. Lesourd, and F. Artigas The effect of the selective 5-HT1A agonists alnespirone (S-20499) and 8-OH-DPAT on extracellular 5-hydroxytryptamine in different regions of rat brain Br. J. Pharmacol. 122 1997 733 741 (Pubitemid 27453100)
13. J.W. Chang, S.R. Wachtel, D. Young, and U.J. Kang Biochemical and anatomical characterization of forepaw adjusting steps in rat models of Parkinson's disease: studies on medial forebrain bundle and striatal lesions Neuroscience 88 1999 617 628 (Pubitemid 28480020)
14. K.A. Chung, N.E. Carlson, and J.G. Nutt Short-term paroxetine treatment does not alter the motor response to levodopa in PD Neurology 64 2005 1797 1798 (Pubitemid 40695823)
15. L. Daws Unfaithful neurotransmitter transporters: focus on serotonin uptake and implications for antidepressant efficacy Pharmacol. Ther. 121 2009 89 99
16. R. de la Fuente-Fernández, M. Schulzer, E. Mak, D.B. Calne, and A. Stoessl Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias Brain 127 2004 2747 2754 (Pubitemid 39627382)
17. K. Dupre, C. Ostock, K. Eskow Jaunarajs, T. Button, L. Savage, W. Wolf, and C. Bishop Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats Exp. Neurol. 229 2011 288 299
18. F. Durif, M. Vidailhet, A. Bonnet, J. Blin, and Y. Agid Levodopa-induced dyskinesias are improved by fluoxetine Neurol 45 1995 1855 1858 (Pubitemid 27122957)
19. K. Eskow-Jaunarajs, M. Angoa-Perez, D. Kuhn, and C. Bishop Potential mechanisms underlying anxiety and depression in Parkinson's disease: consequences of l-DOPA treatment Neurosci. Biobehav. Rev. 35 2011 556 564
20. K.L. Eskow, K.B. Dupre, C.J. Barnum, S.O. Dickinson, J.Y. Park, and C. Bishop The role of the dorsal raphe nucleus in the development, expression, and treatment of l-DOPA-induced dyskinesia in hemiparkinsonian rats Synapse 63 2009 610 620
21. K. Eskow, V. Gupta, S. Alam, J. Park, and C. Bishop The partial 5-HT1A agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy Pharmacol. Biochem. Behav. 87 2007 306 314 (Pubitemid 47101876)
22. C. Goetz, P. Damier, C. Hicking, E. Laska, T. Müller, C. Olanow, O. Rascol, and H. Russ Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial Mov. Disord. 22 2007 179 186 (Pubitemid 46374758)
23. G. Halliday, Y. Li, P. Blumbergs, T. Joh, R. Cotton, P. Howe, W. Blessing, and L. Geffen Neuropathology of immunohistochemically identified brainstem neurons in Parkinson's disease Ann. Neurol. 27 1990 373 385 (Pubitemid 20132052)
24. 1A receptors on l-DOPA-induced rotational behavior in a hemiparkinsonian rat model J. Pharmacol. Sci. 119 2012 10 19
25. M.M. Iravani, K. Tayarani-Binazir, W.B. Chu, M.J. Jackson, and P. Jenner In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with increased motor disability J. Pharmacol. Exp. Ther. 319 2006 1225 1234
26. J. Jankovic Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations Mov. Disord. 20 2005 S11 S16
27. K. Jaunarajs, K. Dupre, A. Steiniger, A. Klioueva, A. Moore, C. Kelly, and C. Bishop Serotonin 1B receptor stimulation reduces D1 receptor agonist-induced dyskinesia NeuroReport 20 2009 1265 1269
28. K. Kannari, H. Shen, A. Arai, M. Tomiyama, and M. Baba Reuptake of l-DOPA-derived extracellular dopamine in the striatum with dopaminergic denervation via serotonin transporters Neurosci. Lett. 402 2006 62 65 (Pubitemid 43766440)
29. 1Breceptors attenuates an increase in extracellular dopamine derived from exogenously administered l-DOPA in the striatum with nigrostriatal denervation J. Neurochem. 76 2001 1346 1353 (Pubitemid 32198239)
30. I.C. Kilpatrick, M.W. Jones, and O.T. Phillipson A semiautomated analysis method for catecholamines, indoleamines, and some prominent metabolites in microdissected regions of the nervous system: an isocratic HPLC technique employing coulometric detection and minimal sample preparation J. Neurochem. 46 1986 1865 1876 (Pubitemid 16095494)
31. M. Komorowski, J. Huston, I. Klingenhegel, J. Paulat, J. Sackers, and B. Topic Distance from source of reward as a marker for extinction-induced "despair": modulation by the antidepressants clomipramine and citalopram Neuroscience 223 2012 152 162
32. W.L. Kuan, J.W. Zhao, and R.A. Barker The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram Psychopharmacol. (Berl.) 197 2008 279 293
33. M. Larsen, M. Sonders, O. Mortensen, G. Larson, N. Zahniser, and S. Amara Dopamine transport by the serotonin transporter: a mechanistically distinct mode of substrate translocation J. Neurosci. 31 2011 6605 6615
34. G. Linazasoro Worsening of Parkinson's disease by citalopram Park. Relat. Disord. 6 2000 111 113 (Pubitemid 30122871)
35. H. Lindgren, D. Andersson, S. Lagerkvist, H. Nissbrandt, and M. Cenci l-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia J. Neurochem. 112 2010 1465 1476
36. M. Lundblad, M. Andersson, C. Winkler, D. Kirik, N. Wierup, and M.A. Cenci Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease Eur. J. Neurosci. 15 2002 120 132 (Pubitemid 35478015)
37. I. Malagié, A. Trillat, C. Jacquot, and A. Gardier Effects of acute fluoxetine on extracellular serotonin levels in the raphe: an in vivo microdialysis study Eur. J. Pharmacol. 286 1995 213 217
38. 1Breceptor agonists in the rat Parkinson model Exp. Neurol. 219 2009 298 307
39. S. Navailles, B. Bioulac, C. Gross, and P. De Deurwaerdère Serotonergic neurons mediate ectopic release of dopamine induced by l-DOPA in a rat model of Parkinson's disease Neurobio. Disord. 38 2010 136 143
40. F. Nilsson, L. Kessing, and T. Bolwig Increased risk of developing Parkinson's disease for patients with major affective disorder: a register study Acta Psychiatr. Scand. 104 2001 380 386 (Pubitemid 34280555)
41. C. Olanow, P. Damier, C. Goetz, T. Mueller, J. Nutt, O. Rascol, A. Serbanescu, F. Deckers, and H. Russ Multicenter, open-label, trial of Sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID study) Clin. Neuropharmacol 27 2004 58 62 (Pubitemid 38569176)
42. N. Pavese, A. Evans, Y. Tai, G. Hotton, D. Brooks, A. Lees, and P. Piccini Clinical correlates of levodopa-induced dopamine release in Parkinson disease: a PET study Neurology 67 2006 1612 1617 (Pubitemid 44747932)
43. G. Paxinos, and W. Watson The Rat Brain in Stereotaxic Coordinates fourth ed. 1998 Academic Press San Diego
44. K. Perry, and R. Fuller Effect of fluoxetine on serotonin and dopamine concentration in microdialysis fluid from rat striatum Life Sci. 50 1992 1683 1690
45. M. Politis, K. Wu, C. Loane, F. Turkheimer, S. Molloy, D. Brooks, and P. Piccini Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structures Neurology 75 2010 1920 1927
46. D.B. Putterman, A.C. Munhall, L.B. Kozell, J.K. Belknap, and S.W. Johnson Evaluation of levodopa dose and magnitude of dopamine depletion as risk factors for levodopa-induced dyskinesia in a rat model of Parkinson's disease J. Pharmacol. Exp. Ther. 323 2007 277 284 (Pubitemid 47443278)
47. L. Rampello, S. Chiechia, R. Raffaele, I. Vecchio, and F. Nicoletti The SSRI, citalopram, improves bradykinesia in patients with Parkinson's disease treated with l-Dopa Clin. Neuropharmacol 25 2002 21 24 (Pubitemid 34178244)
48. D. Rylander, M. Parent, S.S. O'Sullivan, S. Dovero, A.J. Lees, E. Bezard, L. Descarries, and M.A. Cenci Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia Ann. Neurol. 68 2010 619 628
49. Z. Speiser, T. Fine, L. Litinetsky, S. Eliash, E. Blaugrund, and S. Cohen Differential behavioral syndrome evoked in the rats after multiple doses of SSRI fluoxetine with selective MAO inhibitors rasagiline or selegiline J. Neural Transm. 115 2008 107 116
50. J. Taylor, C. Bishop, and P. Walker Dopamine D1 and D2 receptor contributions to l-DOPA-induced dyskinesia in the dopamine-depleted rat Pharmacol. Biochem. Behav. 81 2005 887 893 (Pubitemid 41187824)
51. K. Tuerke, F. Leri, and L. Parker Antidepressant-like effects of paroxetine are produced by lower doses than those with produce nausea Pharmacol. Biochem. Behav. 93 2009 190 195
52. H. Yamato, K. Kannari, H. Shen, T. Suda, and M. Matsunaga Fluoxetine reduces l-DOPA-derived extracellular DA in the 6-hydroxydopamine-lesioned rat striatum Neuroreport 12 2001 1123 1126 (Pubitemid 32374729)
53. F. Zhuo, Y. Lang, R. Salas, L. Zhang, M. de Biasi, and J. Dani Corelease of dopamine and serotonin from striatal dopamine terminals Neuron 46 2005 65 74 (Pubitemid 40488312)